Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Treating Hep C reinfection after liver transplant

Combination therapy with interferon-2b and ribavirin in transplanted patients with chronic Hepatitis C is effective, well tolerated and improves histological outcome, reports the latest issue of Liver International.

News image

fiogf49gjkf04

Recurrence of Hepatitis C virus infection after orthotopic liver transplantation is a virtually universal occurrence.

A significant proportion of patients develop chronic Hepatitis and cirrhosis.

Dr Süleyman Yedibela and colleagues from Germany evaluated the safety and efficacy of interferon-2b plus ribavirin.

After 3 months, 73% of patients were free from Hepatitis C virus RNA
Liver International

The researchers assessed the efficacy of this combination therapy in the treatment of recurrent Hepatitis C after othotopic liver transplantation over the long term.

The research team started 15 patients with recurrent Hepatitis C infection on interferon-2b plus ribavirin 18 months after orthotopic liver transplantation.

Interferon-2b was given as 36 million units and administered subcutaneously 3 times a week, whilst ribavirin was administered at 800 to 1200 mg/day.

The team defined recurrent Hepatitis C infection where there was positive serum Hepatitis C RNA, elevated serum aminotransferases, and histological activity.

Hepatitis C virus RNA was determined 1, 3, 6, 9, 12 and 18 months after initiation of treatment.

The researchers performed liver biopsy before and after therapy and followed up the patients for a mean of 33 months.

The team found that 87% of patients were treated for at least 6 months and 60% for 12 months.

After 3 months, the team noted that 73% were free from Hepatitis C RNA, with less than 50 copies/ml, and that virological end-of-treatment response was 67%.

The researchers observed that 33% remained Hepatitis C RNA-negative 6 months posttreatment.

During the follow-up period, 27% died of liver failure, recurrent Hepatitis C after virological response, or hepatocellular carcinoma.

The researchers found that histological activity index improved significantly for both inflammatory activity and fibrosis, from 9 to 5 and from 7 to 5, respectively.

In none of the patients signs of rejection were observed.

Dr Yedibela's team concludes, “Combination therapy with interferon and ribavirin in transplanted patients with chronic Hepatitis C is an effective treatment that results in a high virological SR rate.”

“It is well tolerated and leads to an improvement in histological outcome.”

Liver Int 2005: 25(4): 717
07 July 2005

Go to top of page Email this page Email this page to a colleague

 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us